MedTrace Logo

Phase 1 ALKS 1140 in Healthy Adults

NCT05019105 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-09-02

No results posted yet for this study

Summary

To evaluate the safety and tolerability of ALKS 1140 in healthy adult subjects

Conditions

Interventions

DRUG

Placebo

Oral matching placebo

DRUG

ALKS 1140

Active oral dose of ALKS 1140

Sponsors & Collaborators

  • Alkermes, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-13
Primary Completion
2022-08-23
Completion
2022-08-23

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05019105 on ClinicalTrials.gov